Keymed Biosciences Inc. (HKG:2162)
Hong Kong
· Delayed Price · Currency is HKD 74.50
-0.75 (-1.00%)
Apr 29, 2026, 4:08 PM HKT
Keymed Biosciences Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Revenue | 716.31 | 428.12 | 354.1 | 100.06 | 110.27 | Upgrade
|
| Revenue Growth (YoY) | 67.31% | 20.91% | 253.87% | -9.26% | - | Upgrade
|
| Cost of Revenue | 88.05 | 12.2 | 36.88 | 2.59 | 17.2 | Upgrade
|
| Gross Profit | 628.27 | 415.92 | 317.22 | 97.48 | 93.07 | Upgrade
|
| Selling, General & Admin | 504.2 | 298.83 | 177.01 | 133.91 | 92.45 | Upgrade
|
| Research & Development | 723.53 | 735.19 | 596.28 | 507.37 | 358.16 | Upgrade
|
| Other Operating Expenses | 30.98 | 7.99 | 1.36 | 0.68 | 2.96 | Upgrade
|
| Operating Expenses | 1,259 | 1,042 | 774.65 | 641.97 | 453.57 | Upgrade
|
| Operating Income | -631.05 | -626.09 | -457.43 | -544.49 | -360.5 | Upgrade
|
| Interest Expense | -16.91 | -18.46 | -17.26 | -8.4 | -11.13 | Upgrade
|
| Interest & Investment Income | 70.19 | 88.33 | 88.35 | 54.32 | 7.01 | Upgrade
|
| Earnings From Equity Investments | -0.67 | -5.26 | -4.75 | -9.71 | -0.72 | Upgrade
|
| Currency Exchange Gain (Loss) | -31.32 | 18.15 | 11.08 | 139.03 | -54.72 | Upgrade
|
| Other Non Operating Income (Expenses) | 58.17 | 34.62 | 23.82 | 65.66 | -13.78 | Upgrade
|
| EBT Excluding Unusual Items | -551.59 | -508.71 | -356.19 | -303.6 | -433.84 | Upgrade
|
| Gain (Loss) on Sale of Investments | 30.87 | 0.06 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -3,459 | Upgrade
|
| Pretax Income | -520.72 | -508.65 | -356.19 | -303.6 | -3,893 | Upgrade
|
| Income Tax Expense | 1.87 | 6.26 | 1.6 | - | - | Upgrade
|
| Earnings From Continuing Operations | -522.6 | -514.91 | -357.79 | -303.6 | -3,893 | Upgrade
|
| Minority Interest in Earnings | -0.04 | -0.33 | -1.57 | -4.52 | 5.32 | Upgrade
|
| Net Income | -522.64 | -515.24 | -359.36 | -308.12 | -3,887 | Upgrade
|
| Net Income to Common | -522.64 | -515.24 | -359.36 | -308.12 | -3,887 | Upgrade
|
| Shares Outstanding (Basic) | 274 | 262 | 261 | 261 | 161 | Upgrade
|
| Shares Outstanding (Diluted) | 274 | 262 | 261 | 261 | 161 | Upgrade
|
| Shares Change (YoY) | 4.59% | 0.22% | 0.09% | 62.34% | 139.72% | Upgrade
|
| EPS (Basic) | -1.91 | -1.97 | -1.37 | -1.18 | -24.17 | Upgrade
|
| EPS (Diluted) | -1.91 | -1.97 | -1.37 | -1.18 | -24.17 | Upgrade
|
| Free Cash Flow | - | -997.55 | -682.11 | -680.76 | -386.42 | Upgrade
|
| Free Cash Flow Per Share | - | -3.81 | -2.61 | -2.61 | -2.40 | Upgrade
|
| Gross Margin | 87.71% | 97.15% | 89.59% | 97.42% | 84.40% | Upgrade
|
| Operating Margin | -88.10% | -146.24% | -129.18% | -544.15% | -326.93% | Upgrade
|
| Profit Margin | -72.96% | -120.35% | -101.49% | -307.92% | -3525.30% | Upgrade
|
| Free Cash Flow Margin | - | -233.00% | -192.63% | -680.33% | -350.44% | Upgrade
|
| EBITDA | -556.04 | -551.07 | -405.8 | -522.22 | -347.7 | Upgrade
|
| EBITDA Margin | -77.63% | -128.72% | -114.60% | - | - | Upgrade
|
| D&A For EBITDA | 75.01 | 75.01 | 51.63 | 22.27 | 12.8 | Upgrade
|
| EBIT | -631.05 | -626.09 | -457.43 | -544.49 | -360.5 | Upgrade
|
| EBIT Margin | -88.10% | -146.24% | -129.18% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.